Keyphrases
Atezolizumab Plus Bevacizumab
100%
Hepatocellular Carcinoma
100%
Immune-related
100%
Aseptic Meningitis
100%
Immune Checkpoint Inhibitors
66%
Contrast Enhancement
66%
Advanced Hepatocellular Carcinoma
66%
Atezolizumab
66%
Immune-related Adverse Events
66%
Cerebral Sulci
66%
Anorexia
33%
Fever
33%
Clinical Symptoms
33%
Malignancy
33%
Cell Count
33%
Steroid Therapy
33%
Serious Complications
33%
Older Women
33%
Protein Level
33%
Treatment Cycle
33%
Cell Wall Proteins
33%
Cerebrospinal Fluid Examination
33%
Rare Complication
33%
Dynamic Contrast-enhanced Magnetic Resonance Imaging (DCE-MRI)
33%
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Atezolizumab
100%
Bevacizumab
100%
Aseptic Meningitis
100%
Immunity
100%
Immune Checkpoint Inhibitor
50%
Immune-Related Adverse Events
50%
Anorexia
25%
Cancer
25%
Magnetic Resonance Imaging
25%
Cell Count
25%
Steroid Therapy
25%
Infection
25%
Case Presentation
25%
Clinician
25%
Cerebrospinal Fluid Examination
25%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Atezolizumab
100%
Bevacizumab
100%
Aseptic Meningitis
100%
Adverse Event
50%
Immune Checkpoint Inhibitor
50%
Infection
25%
Anorexia
25%